Side-by-side · Research reference

CrystagenvsGHRP-2

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BPhase 2HUMAN-REVIEWED15/42 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

GHRP-2

Hexapeptide GHRP · Phase 2 (clinical diagnostic)

100–300 mcgPer doseBowers 1990

Phase 2Evidence levelBowers 1990 Sigalos 2018

~30 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

Crystagen

GHRP-2

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

Yes, with somatostatin feedback active

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

GHRP-2

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

100–300 mcg per injectionBowers 1990

Evidence basis

Animal / mechanistic

Phase 2 + clinical diagnostic useBowers 1990

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

1–3× per day

Duration

Unknown — chronic administration presumed in animal models

8–12 weeks on / 4 off (anecdotal)

Half-life

Not reported

~30 minMalagón 1999

Lower / starter dose

—

50 mcg per dose

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep + fasted preferred

04Side Effects & Safety

Parameter

Crystagen

GHRP-2

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Cortisol elevation

—

Mild but measurableBowers 1990

Prolactin elevation

—

Mild but measurable

Hunger

—

Strong appetite increase

Injection site reaction

—

Mild erythema

IGF-1 elevation

—

Strong; monitor with chronic high-dose use

Cancer risk

—

Contraindicated in active malignancy

Pregnancy / OB

—

Avoid

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

GHRP-2

·Active malignancy
·Pregnancy / breastfeeding

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

GHRP-2

·Untreated diabetes

05Administration Protocol

Parameter

Crystagen

GHRP-2

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

SQ — abdomen or thigh. Rotate sites.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Pre-sleep + fasted preferred.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

GHRP-2

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

GHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.

GHRP-2: 100–200 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: High-amplitude GH pulse, body composition

Bowers 1990 Teichman 2006